Compare Gilead Sciences, Inc. (GILD) vs Pinterest Inc (PINS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Pinterest Inc — how do they compare? Gilead Sciences, Inc. trades at $136.49 (market cap $168.35B), while Pinterest Inc trades at $22.9 (market cap $13.45B). The key difference: Gilead Sciences, Inc. is far larger — about 12.5× Pinterest Inc's market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Pinterest Inc pays none. Which is the better fit depends on your goals.
| GILD | PINS | |
|---|---|---|
Market Cap | $168.35B | $13.45B |
Sector | Health | Media |
52-Week High | $155.80 | $37.95 |
52-Week Low | $110.56 | $15.42 |
Enterprise Value | $191.42B | $13.37B |
Dividend Yield | 2.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Pinterest (PINS) trades at $24.37, up 2.91% with strong technical momentum as moving averages signal bullish sentiment. The company demonstrates solid fundamental performance with Q2 2026 EPS beating estimates at $0.43 versus $0.36 expected, marking the third consecutive quarterly beat. Revenue growth remains robust at 18% year-over-year, reaching $1.18 billion in Q2 2026, while maintaining a healthy gross profit margin of 79.47%.
The investment outlook appears favorable with 54% analyst buy ratings and a $28.69 consensus price target representing 18% upside potential. However, risks include intense advertising competition from Meta and slowing revenue guidance for Q3 2026. The stock offers value at current levels given strong AI-driven ad growth and record user metrics, though investors should monitor competitive pressures and execution on international expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →
